Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Dakota Wealth Management

Dakota Wealth Management increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 13.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,468 shares of the medical equipment provider’s stock after purchasing an additional 409 shares during the period. Dakota Wealth Management’s holdings in Lantheus were worth $310,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of LNTH. Envestnet Asset Management Inc. boosted its stake in shares of Lantheus by 0.3% during the second quarter. Envestnet Asset Management Inc. now owns 111,498 shares of the medical equipment provider’s stock worth $8,952,000 after buying an additional 356 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in Lantheus during the 2nd quarter valued at approximately $209,000. Benjamin F. Edwards & Company Inc. acquired a new stake in Lantheus during the 2nd quarter worth approximately $80,000. Pacer Advisors Inc. grew its stake in shares of Lantheus by 11.5% in the 2nd quarter. Pacer Advisors Inc. now owns 15,711 shares of the medical equipment provider’s stock valued at $1,261,000 after purchasing an additional 1,618 shares during the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of Lantheus by 259.2% in the second quarter. Mackenzie Financial Corp now owns 15,571 shares of the medical equipment provider’s stock valued at $1,250,000 after purchasing an additional 11,236 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Down 0.1 %

Shares of NASDAQ LNTH opened at $97.50 on Friday. The firm has a 50-day moving average price of $91.11 and a 200 day moving average price of $100.56. Lantheus Holdings, Inc. has a 52 week low of $50.42 and a 52 week high of $126.89. The stock has a market capitalization of $6.78 billion, a price-to-earnings ratio of 16.22 and a beta of 0.46.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial reaffirmed a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average price target of $131.86.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.